Cross‐Sectional and Longitudinal Diagnostic Performance of Plasma p‐tau217 and p‐tau217/Aβ42 in Alzheimer's Disease

Authors:

Abstract
Objective: Recent studies suggest that combining plasma phosphorylated tau (p‐tau) with β ‐amyloid (A β ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross‐sectional and longitudinal concordance of these markers with A β positron emission tomography (PET) positivity remains incompletely understood. This study aimed to evaluate the diagnostic performance of plasma p‐tau, alone and in combination with plasma A β , in AD. Methods: We included 326 participants from the Alzheimer's Disease Neuroimaging Initiative and 357 Chinese older adults from the Greater‐Bay‐Area Healthy Aging Brain Study who underwent A β ‐PET imaging. Longitudinal data were available for 285 Alzheimer's Disease Neuroimaging Initiative participants. Plasma p‐tau181, p‐tau217, A β 42, and A β 40 were measured on different analytical platforms. Diagnostic performance for A β ‐PET positivity was assessed using a two‐cutoff approach. Results: Combining plasma p‐tau with A β 42 or the A β 42/40 ratio reduced the intermediate zone. Notably, p‐tau217/A β 42 showed stronger agreement with A β ‐PET positivity than p‐tau217 alone. Among individuals classified as p‐tau217/A β 42 positive but p‐tau217 intermediate, 57.1 to 83.3% were A β ‐PET positive. Longitudinally, most Stable Positive (88.0–96.1%) and Stable Negative (89.4–90.9%) cases defined by p‐tau217 or p‐tau217/A β 42 were A β ‐PET positive and A β ‐PET negative, respectively. Critically, 69.7 to 75.8% of Non‐positive to Positive cases defined by p‐tau217/A β 42 were A β ‐PET positive. Interpretation: These findings provide novel insights into the cross‐sectional and longitudinal diagnostic performance of plasma p‐tau217/A β 42 in AD. To be specific, plasma p‐tau217/A β 42 can reduce the intermediate zone and improve agreement with A β ‐PET positivity, and longitudinal p‐tau217/A β 42 monitoring is particularly informative for identifying A β ‐PET–positive patients who were p‐tau217/A β 42 negative or intermediate at baseline and were misclassified as low risk of AD. ANN NEUROL 2026;100:998–1011

This publication has 46 references indexed in Scilit: